Windtree Therapeutics Faces Delisting from Nasdaq, Shares Plunge Amidst Financial Struggles

Windtree Therapeutics is facing delisting from the Nasdaq Capital Market after failing to meet a minimum $1 bid price requirement for 30 consecutive business days. The company’s shares have plummeted as a result, with trading suspended pending official notification. Despite raising $60 million in recent funding and securing a $520 million BNB financing deal, Windtree is facing financial challenges, reporting a significant net loss of $10.64 million. 30-day non-compliance with Nasdaq’s listing criteria triggered the delisting notice, which will go into effect on August 21st, 2025. The company has not issued any public statements beyond official filings.